Properties of the Measures to Assess Oxaliplatin-induced Peripheral Neuropathy: A Literature Review.
10.4040/jkan.2015.45.6.783
- Author:
Sang Hui CHU
1
;
Yoon Ju LEE
;
Young Joo LEE
;
Charles S CLEELAND
Author Information
1. College of Nursing, Yonsei University, Seoul, Korea.
- Publication Type:Review
- Keywords:
Oxaliplatin;
Peripheral nervous system diseases;
Symptom assessment;
Psychometrics
- MeSH:
Activities of Daily Living;
Antineoplastic Agents/*adverse effects/therapeutic use;
Databases, Factual;
Humans;
Neoplasms/drug therapy;
Organoplatinum Compounds/*adverse effects/therapeutic use;
Peripheral Nervous System Diseases/*etiology;
Psychometrics
- From:Journal of Korean Academy of Nursing
2015;45(6):783-801
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
PURPOSE: The purpose of this study is to provide a comprehensive overview of the various measures available for assessment of oxaliplatin-induced peripheral neuropathy (OXLIPN) and to evaluate the measurement properties of each assessment tool. METHODS: A systematic review was conducted to identify existing measures for OXLIPN found in the databases of PubMed, Cochrane Library, Embase, RISS and KoreaMed. The quality of the 24 identified tools was evaluated based on their properties of measurement including content validity, internal consistency, criterion validity, construct validity, reproducibility, responsiveness, floor-ceiling effects and interpretability. RESULTS: Ten (41.7%) of the 24 tools were identified as specific measures for assessing OXLIPN and the most popular type of measures were clinical grading systems by clinicians (58.3%) and only 29.2% of measures were identified as patient reported outcomes. The most frequently used tool was National Cancer Institute-Common Toxicity Criteria (NCI-CTC), but the validity of NCI-CTC has not been reported appropriately. Overall, the Neuropathic Pain Symptom Inventory (NPSI) received the best psychometric scores, and the Chemotherapy-induced Peripheral Neuropathy Assessment Tool (CIPNAT) and Functional Assessment of Cancer Therapy/Gynaecologic Oncology Group-neurotoxicity-12 (FACT/GOG-Ntx-12) followed NPSI. CONCLUSION: To select appropriate measure, evidences should be accumulated through the clinical use of tools. Therefore, practitioner and researchers are urged to report relevant statistics required for the validation of the currently used measures for assessment of OXLIPN.
